Abstract
The authors report the case of a patient with malignant thymoma unresponsive to combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] and cisplatin/VP-16) who subsequently achieved clinical response to continuous daily prednisone. A review of the literature indicates that prednisone and cisplatin are the most active agents in the treatment of malignant thymoma.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Fluoxymesterone / administration & dosage
-
Humans
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Red-Cell Aplasia, Pure / chemically induced
-
Thymoma / drug therapy*
-
Thymoma / radiotherapy
-
Thymus Neoplasms / drug therapy*
-
Thymus Neoplasms / radiotherapy
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Fluoxymesterone
-
Cisplatin
-
Prednisone